TRA2B and ovarian cancer: While its oncogenic role has been reviewed previously [10], recent research continues to explore TRA2β’s specific therapeutic potential in ovarian cancer [23], squamous cell carcinoma [38,39,40], and colon adenocarcinoma [41].